Localization Mechanisms of Radiopharmaceuticals Practice Test

Understanding why transporter-mediated tracers are preferred in tumors with low perfusion hinges on how uptake occurs. Many imaging tracers rely on delivery through blood vessels, so when perfusion is poor, delivery is limited and the signal drops. Transporter-mediated tracers, on the other hand, are designed to be substrates for specific transport proteins that are often overexpressed in tumor cells. Once the tracer reaches the tumor, these transporters actively ferry it into cells and, in many designs, trap it inside, so the tracer can accumulate even when blood flow is limited. This uptake reflects cellular transporter activity and tumor biology rather than just vascular delivery, improving visualization in poorly perfused regions. Tracers that depend on perfusion would underperform where blood flow is scarce, and non-specific binding would lead to vague, non-selective signals. Therefore, the key reason is that uptake is driven by specific transporters enabling accumulation despite limited blood flow.